Nabriva Therapeutics AG Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Nabriva Therapeutics last-minute Real Value cannot be determined due to lack of data. The latest price of Nabriva Therapeutics is $0.0. Our model forecasts the value of Nabriva Therapeutics from analyzing the firm fundamentals such as Return On Equity of -2.69, current valuation of 3.29 M, and Profit Margin of (1.48) % as well as examining its technical indicators and probability of bankruptcy.
Nabriva Therapeutics Total Value Analysis
Nabriva Therapeutics AG is now projected to have valuation of 3.29 M with market capitalization of 4.55 M, debt of 5.22 M, and cash on hands of 20.04 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Nabriva Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.29 M | 4.55 M | 5.22 M | 20.04 M |
Nabriva Therapeutics Investor Information
The company has price-to-book ratio of 0.24. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Nabriva Therapeutics recorded a loss per share of 19.67. The entity last dividend was issued on the 3rd of December 2020. The firm had 1:25 split on the 16th of September 2022. Based on the key indicators related to Nabriva Therapeutics' liquidity, profitability, solvency, and operating efficiency, Nabriva Therapeutics AG is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Nabriva Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Nabriva Therapeutics has an asset utilization ratio of 112.29 percent. This indicates that the Company is making $1.12 for each dollar of assets. An increasing asset utilization means that Nabriva Therapeutics AG is more efficient with each dollar of assets it utilizes for everyday operations.Nabriva Therapeutics Ownership Allocation
Roughly 90.27 % of Nabriva Therapeutics outstanding shares are held by general public with 0.96 pct. owned by insiders and only 8.77 % by institutional investors.Nabriva Therapeutics Profitability Analysis
The company reported the previous year's revenue of 35.67 M. Net Loss for the year was (57.19 M) with loss before overhead, payroll, taxes, and interest of (10.23 M).Nabriva Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Nabriva Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 2.7 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Nabriva Stock
If you are still planning to invest in Nabriva Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Nabriva Therapeutics' history and understand the potential risks before investing.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |